• 1
    Steinberg D, Witztum JL. Is the oxidative modifications hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date reflect the hypothesis? Circulation 2002; 105: 21072111.
  • 2
    Parthasarathy S, Santanam N, Auge N. Oxidised low-density lipoprotein: a two-faced Janus in coronary artery disease? Biochem Pharmacol 1998; 56: 279284.
  • 3
    Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 112.
  • 4
    Rubins HB Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al . for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410418.
  • 5
    Mackness MI, Durrington PN, Mackness B. How HDL protects against the effects of lipid peroxidation. Curr Opinion Lipidol 2000; 11: 383388.
  • 6
    Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts 1991; 286: 152154.
  • 7
    Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129135.
  • 8
    Watson AD, Berliner JA, Hama SY, La Du BN, Fault KF, Fogelman AM et al . Protective effect of high-density lipoprotein associated paraoxonase—inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 96: 28822891.
  • 9
    Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S et al . Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284287.
  • 10
    Ferretti G, Baccletti T, Bushi D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high density lipoproteins against erythrocyte membrane peroxidation: a comparison between healthy subjects and Type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 29572962.
  • 11
    Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW et al . Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 20392046.
  • 12
    Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 2004; 318: 680683.
  • 13
    Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuashia B et al . Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 139: 341349.
  • 14
    Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI. Low paraoxonase activity in Type II diabetes complicated by retinopathy. Clin Sci 2000; 98: 355363.
  • 15
    Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in Type 1 diabetic patients compared to non-diabetic, first-degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229235.
  • 16
    Sampson MJ, Braschi S, Willis G, Astley SB. Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised, plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond) 2005; 109: 189197.
  • 17
    Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K et al . Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with Type 2 diabetes. Metabolism 2004; 53: 297302.
  • 18
    Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human serum paraoxonase 1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscl Thromb Vasc Biol 2006; 26: 15451550.
  • 19
    Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733749.
  • 20
    Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al . Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312320.
  • 21
    Feretti G, Baccheti T, Marchionni C, Calderetti L, Curatola T. Effect of glycation of high-density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38: 163169.
  • 22
    Mastorikou M, Mackness M, Mackness B. Defective metabolism of oxidised-phospholipids by high-density lipoprotein from people with Type 2 diabetes. Diabetes 2006; 55: 30993103.
  • 23
    WHO. Second Report of the WHO Expert Committee on Diabetes Mellitus. WHO Technical Report Series No. 646. Geneva: World Health Organization, 1980.
  • 24
    Mackness MI, Durrington PN. Lipoprotein separation and analysis for clinical studies. In: ConverseCA, SkinnerER, eds. Lipoprotein Analysis: A Practical Approach. Oxford: IRL Press, 1992; 142.
  • 25
    Tames FJ, Mackness MI, Arrol S, Laing I, Durrington PN. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992; 93: 237244.
  • 26
    Chisholm GM, Penn MS. Oxidised lipoproteins and atherosclerosis. In: FusterV, RossR, TopolEJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven, 1996; 129149.
  • 27
    Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, stimulation of lipo-lactonase and macrophage cholesterol efflux. J Lipid Res 2006; 47: 24922502.
  • 28
    Rosenblat M, Karry R, Aviram M. Paraoxonase1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein deficient serum: relevance to diabetes. Atherosclerosis 2006; 187: 7481.
  • 29
    Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M et al . Low paraoxonase activity predicts coronary events in the Caerphilly prospective Study. Circulation 2003; 107: 27752779.
  • 30
    Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmac 1998; 31: 329336.
  • 31
    Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334336.
  • 32
    Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998; 423: 5760.
  • 33
    Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al . Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 1998; 10: 16171624.